NL-OMON23430已完成不适用
Anti-CD20 treatment of relapsed or refractory Immune Thrombocytopenic Purpura (ITP) after first line corticosteroid treatment.
未提供0 个研究点目标入组 150 人开始时间: 待定最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 150
研究概览
简要总结
/A
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Age minimal 18 years;
排除标准
- •1. The presence of an accessory spleen in splenectomized patients;
研究者
相似试验
已完成
不适用
Anti-CD20 treatment of relapsed or refractory immune thrombocytopaenic purpura (ITP) after first line corticosteroid treatmentImmune thrombocytopaenic purpura (ITP)Haematological DisordersPurpura and other haemorrhagic conditionsISRCTN16619820Dutch Haemato-Oncology Association (Stichting Hemato-Oncologie Volwassenen Nederland) (HOVON) (The Netherlands) - Data Centre150
尚未招募
不适用
Anti-CD20 therapy for the treatment ofchronic graft versus host disease.30 patients with a steroid refractory cGVHD will be treated with anti-B-cell therapyNL-OMON27646Roche Nederland B.V.30
已完成
不适用
ANTI-CD20 THERAPY FOR THE TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASEchronic graft-versus-host disease, allogeneic stem cell transplantation, B-cell depletionNL-OMON27822niversity Medical Centre UtrechtP.O. Box 855003508 GA Utrecht, The Netherlands30
已完成
不适用
Anti-CD20 therapy for the treatment of chronic Graft Versus Host DiseaseChronic Graft Versus Host Disease (cGVHD)Injury, Occupational Diseases, PoisoningFailure and rejection of transplanted organsISRCTN43525354niversity Medical Center Utrecht (UMCU) (The Netherlands)30
已完成
不适用
Anti-CD20 monoclonal antibody therapy for type II mixed cryoglobulinemia syndromeMixed cryoglobulinemia HCV- related or unrelatedHaematological DisordersCryoglobulinaemiaISRCTN55287110niversity of Udine (Italy)124